Particle.news
Download on the App Store
6 ARTICLES
·
last wk.

Nanoparticle 'Super Adjuvant' Vaccine Blocks Multiple Cancers in Mice

The peer-reviewed mouse study introduces a dual-adjuvant lipid nanoparticle platform now headed toward translation through a new startup, with human testing yet to begin.

A new way of delivering vaccines using nanoparticles could prevent or slow down a number of different cancers in mice.
Cancer Vaccine Blocks Multiple Tumors in Mice For 250 Days
Image
Image

Overview

  • UMass Amherst researchers reported the results in Cell Reports Medicine, detailing a vaccine that pairs tumor antigens with a dual-adjuvant lipid nanoparticle.
  • The formulation generated strong tumor-specific T‑cell responses and systemic immune memory, which researchers cite as key to the survival benefit.
  • In a melanoma prevention model, 80 percent of vaccinated mice remained tumor‑free for the full 250‑day study, while controls died within 35 days.
  • Using tumor lysate as the antigen, tumor rejection rates reached 88 percent for pancreatic, 75 percent for triple‑negative breast, and 69 percent for melanoma, and vaccinated mice did not develop lung tumors in metastasis challenges.
  • The team has formed NanoVax Therapeutics to pursue development, and they note further tolerability studies and eventual clinical trials are needed to assess safety and efficacy in humans.